Evidence map›Paper›PMID 37768476›Full record

ReviewThe protein journal2023

Protein Kinases and their Inhibitors Implications in Modulating Disease Progression.

Rabiya Ahsan, Mohd Muazzam Khan, Anuradha Mishra, Gazala Noor, Usama Ahmad

Abstract readReview
PubMed Publisher
In one paragraph

Review in The protein journal, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Rabiya AhsanDepartment of pharmacology, Faculty of Pharmacy, Integral University, Lucknow, India.
Mohd Muazzam KhanDepartment of pharmacology, Faculty of Pharmacy, Integral University, Lucknow, India. Khanmuazzam936@gmail.com.
Anuradha MishraDepartment of pharmacology, Amity Institute of Pharmacy, Amity University, sector 125, Noida, Uttar Pradesh, 201313, India.
Gazala NoorDepartment of pharmacology, Faculty of Pharmacy, Integral University, Lucknow, India.
Usama AhmadDepartment of pharmaceutics, Faculty of Pharmacy, Integral University, Lucknow, India.
Integral University · INAmity University · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Protein phosphorylation plays an important role in cellular pathways, including cell cycle regulation, metabolism, differentiation and survival. The protein kinase superfamily network consists of 518 members involved in intrinsic or extrinsic interaction processes. Protein kinases are divided into two categories based on their ability to phosphorylate tyrosine, serine, and threonine residues. The complexity of the system implies its vulnerability. Any changes in the pathways of protein kinases may be implicated in pathological processes. Therefore, they are regarded as having an important role in human diseases and represent prospective therapeutic targets. This article provides a review of the protein kinase inhibitors approved by the FDA. Finally, we summarize the mechanism of action of protein kinases, including their role in the development and progression of protein kinase-related roles in various pathological conditions and the future therapeutic potential of protein kinase inhibitors, along with links to protein kinase databases. Further clinical studies aimed at examining the sequence of protein kinase inhibitor availability would better utilize current protein kinase inhibitors in diseases. Additionally, this review may help researchers and biochemists find new potent and selective protein kinase inhibitors and provide more indications for using existing drugs.

Indexed as

NeoplasmsProtein Kinase InhibitorsProtein KinasesAnimalsDisease ProgressionHumansPhosphorylationProtein Kinase InhibitorsProtein KinasesCycle regulationPathologicalPhosphorylateProgressionProtein kinaseVulnerability

Identifiers

PMID37768476
OpenAlexW4387115148

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.